We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Eli Lilly and Co | NYSE:LLY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 31.13 | 4.24% | 766.10 | 766.99 | 736.00 | 738.04 | 3,397,607 | 01:00:00 |
From May 2019 to May 2024
By Colin Kellaher
Eli Lilly & Co. and Boehringer Ingelheim Tuesday said the U.S. Food and Drug Administration granted fast-track designation for the development of their diabetes drug Jardiance to improve outcomes following a heart attack.
The companies in May announced plans plan to study whether Jardiance can help prevent hospitalization for heart failure and reduce the risk of mortality in patients with and without diabetes who have had an acute myocardial infarction, more commonly known as a heart attack.
The FDA's fast-track program is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.
Indianapolis-based drug maker Eli Lilly and Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Germany, jointly market Jardiance as part of a 2011 alliance.
The companies are currently exploring the impact of Jardiance on patients across the spectrum of cardio-renal-metabolic conditions.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 15, 2020 08:32 ET (12:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Eli Lilly Chart |
1 Month Eli Lilly Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
